[Osteoprotegerin: regulator, protector and marker].
Experimental and clinical trials in the field of bone biology helped to clarify the role of receptors, which belong to the tumor necrosis factor family, such as osteoprotegerin and receptor activator of nuclear factor kappaB (RANK), in the regulation of bone remodeling. The ligand of the receptor activator of nuclear factor kappaB (RANKL) is a stimulator of bone resorption, while osteoprotegerin is the soluble "decoy" receptor to RANKL, protecting thereby bone from resorption. Pathological states of bone remodeling (like osteoporosis) are associated with imbalance in the activity of osteoprotegerin and the receptor activator of nuclear factor kappaB. Recent studies, however, also indicate that the osteoprotegerin/RANKL/RANK system has important roles in the regulation of the immune and vascular system as well. In this review we summarize the function and regulation of osteoprotegerin, its role in pathological states--primarily in cardiovascular diseases--and its relevance as a marker of cardiovascular risk. Finally, we present our prospective trial performed among the chronic dialyzed patients, where we examined the association between the cardiovascular mortality, osteoprotegerin levels and the arterial stiffness.
El Hadj Othmane
Taha
T
Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Budapest. tahaothmane@yahoo.com
Speer
Gábor
G
Fekete
Bertalan
B
Szabó
Tamás
T
Egresits
József
J
Fodor
Erzsébet
E
Kiss
István
I
Nemcsik
János
J
Szabó
András
A
Németh
Zsófia
Z
Szathmári
Miklós
M
Tislér
András
A
D000368:Aged; D000704:Analysis of Variance; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001783:Blood Flow Velocity; D001847:Bone Diseases / Q000378:metabolism; D016723:Bone Remodeling / Q000502:physiology; D002114:Calcinosis; D002318:Cardiovascular Diseases / Q000378:metabolism; D002339:Carotid Arteries / Q000473:pathology; D005260:Female; D005263:Femoral Artery / Q000473:pathology; D006339:Heart Rate; D006801:Humans; D053208:Kaplan-Meier Estimate; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood / Q000378:metabolism*; D011446:Prospective Studies; D053245:RANK Ligand / Q000378:metabolism*; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000378:metabolism*; D006435:Renal Dialysis; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D014652:Vascular Diseases / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D014655:Vascular Resistance; D014664:Vasodilation
D015415:Biomarkers; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B
Osteoprotegerin: a regulátor, a protektor és a marker. Osszefoglalás irodalmi adatok és saját eredményeink alapján.